Oct. 10, 2020

When Steve and I first started Diabetes in Control we tried to attend every conference and speak to every thought leader we could find. Back then pharmacists did not garner a lot of respect from endocrinologists, and often we were blown off for every interview. There were a few who were willing to take time with us, and one of those was Julio Rosenstock from the Dallas Diabetes Research Center. He was always on the cutting edge of diabetes research and would always take time to talk to us.

Because of this I am always happy to share his research with you, our readers.

This week our intern, Alexandria Bartley, PharmD. Candidate, FAMU College of Pharmacy, reviewed his research on a once-a-week insulin. As I sat there reading her article, I thought, wouldn’t it be great if a patient could take  1 injection of insulin icodec and 1 injection of a weekly GLP-1 mimic and be done for the week.

Note: Don’t miss part 2 of our special feature on “The Future of Type 2 Diabetes Management and The Changing Roles of Healthcare Professionals,” presented in three parts. The series is about how a team of physicians and pharmacists at St. Elizabeth Healthcare in Kentucky uses artificial intelligence to improve treatment, adherence, and cost savings for both Medicaid and Americans, and to get the patient to goal in a shorter period.

 

*****************************

We can make a difference!

*****************************

Dave Joffe

Editor-in-chief